Liraglutide Market (Updated Version Available)

Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.
The total amount of Patents about Liraglutide are 1871, among those Patents, 44%is about application, 26%is about Combination therapy, and 12%is about Preparation method.
In these patents, accounting for Europe is the largest, followed by North America, and finally Asia.
The application of Liraglutide
Liraglutide for the treatment of type 2 diabetes mellitus
Liraglutide 1.2 mg daily in triple therapy regimens (in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione) is recommended as an option for the treatment of people with type 2 diabetes, only if used as described for exenatide in 'Type 2 diabetes: the management of type 2 diabetes'
Liraglutide 1.2 mg daily in dual therapy regimens (in combination with metformin or a sulphonylurea) is recommended as an option for the treatment of people with type 2 diabetes, only if the person is intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and the person is intolerant of thiazolidinediones and dipeptidyl peptidase-4 (DPP-4) inhibitors, or treatment with thiazolidinediones and DPP-4 inhibitors is contraindicated.
Liraglutide 1.8 mg daily is not recommended for the treatment of people with type 2 diabetes.
The Committee concluded that the evidence provided was not robust enough to allow it to recommend liraglutide as a cost-effective alternative to either thiazolidinediones or DPP-4 inhibitors as a triple therapy regimen, however it believes liraglutide is a cost-effective treatment option relative to exenatide.

Taking into account the lack of clinical trial evidence showing a significant benefit from increasing the liraglutide dose from 1.2 mg to 1.8 mg, the widely varying ICERs and the uncertainty in the economic analysis, the Committee was unable to recommend liraglutide 1.8 mg for the treatment of type 2 diabetes.
The Committee concluded that people with type 2 diabetes currently receiving liraglutide who do not meet the criteria specified in section 1.1 or 1.3, or who are receiving liraglutide 1.8 mg, should have the option to continue their current treatment until they and their clinicians consider it appropriate to stop.


The report offers detailed coverage of Liraglutide industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Liraglutide by geography. The report splits the market size, by volume and value, on the basis of application type and geography.

The report forecast global Liraglutide market to grow to reach xxx Million USD in 2020 with a CAGR of xx% during the period 2021-2027.

First, this report covers the present status and the future prospects of the global Liraglutide market for 2015-2027.
And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].

Key Companies
HEC Pharm
Bachem
Bharat Pharmaceuticals
Kingpep Biotechnology
Shenzhen JYMed Technology
Wuxi Asiapeptide
AmbioPharm
At the same time, we classify Liraglutide according to the type, application by geography. More importantly, the report includes major countries market based on the type and application.

Market Segment as follows:
Market by Order Type
Pills
Liquid
Market by Application
Hospital
Drug Store

By Region
Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America[United States, Canada, Mexico]
Middle East & Africa[GCC, North Africa, South Africa]
South America[Brazil, Argentina, Columbia, Chile, Peru]

The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Liraglutide market for the forecast period 2021 - 2027?
• What are the driving forces in the Liraglutide market for the forecast period 2021 - 2027?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Liraglutide industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?